This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| European Cystic Fibrosis Society Patient Registry | |
|---|---|
| Name | European Cystic Fibrosis Society Patient Registry |
| Abbreviation | ECFS PR |
| Formation | 2003 |
| Type | Medical registry |
| Headquarters | Rome |
| Region served | Europe |
European Cystic Fibrosis Society Patient Registry The European Cystic Fibrosis Society Patient Registry collects standardized clinical, demographic and treatment data on people with cystic fibrosis across multiple countries to support research, quality improvement and health policy. The Registry operates within a landscape that includes national health systems such as National Health Service (England), supranational bodies such as the European Commission, professional societies such as the European Cystic Fibrosis Society, and research consortia such as the European Respiratory Society and the European Medicines Agency. Its activities intersect with institutions including the World Health Organization, the European Centre for Disease Prevention and Control, and academic centers such as University College London, Karolinska Institutet, and Charité – Universitätsmedizin Berlin.
The Registry aggregates longitudinal data from clinics in member countries to enable epidemiological surveillance, outcome benchmarking and translational research involving stakeholders like the European Society for Paediatric Gastroenterology Hepatology and Nutrition, the International Society for Pharmaceutical Engineering, and funding bodies such as the Wellcome Trust and the Horizon 2020 programme. Data contributors include national registries such as the Cystic Fibrosis Foundation Patient Registry and networks like the European Reference Network on Rare and Complex Diseases (ERN-Rare)]. The Registry’s outputs inform guideline committees such as those convened by the European Respiratory Society and regulatory decisions by the European Medicines Agency.
The Registry was established in response to collaborative initiatives promoted by the European Cystic Fibrosis Society and early surveillance activities at centers including Great Ormond Street Hospital, Alder Hey Children's Hospital, and Hôpital Necker–Enfants Malades. Key milestones involved partnerships with research institutions such as Imperial College London, University of Oxford, and Ghent University, and policy dialogues with the Council of Europe and the European Parliament. Expansion phases paralleled advances in genomics at institutions like the Wellcome Sanger Institute and clinical trials hosted by networks linked to Oxford University Hospitals and Hôpital Universitaire Pitié Salpêtrière.
Governance structures draw upon expertise from academic bodies such as Universitätsklinikum Heidelberg, patient organizations like Cystic Fibrosis Trust, and international funders including the European Commission and philanthropic organizations such as the Bill & Melinda Gates Foundation. Steering committees include representatives from national registries such as the Cystic Fibrosis Foundation and centers of excellence like SickKids Hospital and Addenbrooke's Hospital. Funding streams have combined grants from programmes like Horizon Europe, contracts with agencies such as the European Centre for Disease Prevention and Control, and collaborations with industry partners including Vertex Pharmaceuticals and Roche under governance frameworks influenced by legal instruments such as the General Data Protection Regulation.
Data capture follows standardized case report forms developed with clinical input from specialists at Royal Brompton Hospital, Sahlgrenska University Hospital, and Erasmus University Medical Center, and methodological advice from epidemiologists affiliated with Karolinska Institutet and Université Paris Cité. Variables encompass demographics, genotype data reflecting variants catalogued in databases tied to Human Genome Organisation, pulmonary function metrics used in trials at Moorfields Eye Hospital-linked respiratory units, and treatment histories including modulators produced by companies such as Vertex Pharmaceuticals. Quality assurance draws on statistical methods promoted by groups at London School of Hygiene & Tropical Medicine and Institute of Clinical Epidemiology, University of Bern.
Researchers from institutions such as University of Edinburgh, Ghent University, and University of Milan have used Registry data for studies on survival trends, genotype–phenotype correlations, and health-economic modelling that inform guidelines from the European Respiratory Society and reimbursement decisions evaluated by national agencies like the National Institute for Health and Care Excellence. Outputs include multi-center cohort studies comparable to work from the Cystic Fibrosis Foundation and randomized trial support similar to research coordinated by European Clinical Research Infrastructure Network. Findings have been presented at conferences such as the European Cystic Fibrosis Conference, the European Respiratory Society International Congress, and published by journals including The Lancet Respiratory Medicine and European Respiratory Journal.
Ethical oversight has involved institutional review boards at centers like University Hospital Geneva, compliance with the General Data Protection Regulation, and consultations with patient advocacy groups including Cystic Fibrosis Europe. Data governance frameworks have been modeled after best practices from registries overseen by World Health Organization collaborations and legal guidance from the European Data Protection Supervisor. Procedures for informed consent, pseudonymization, and secure data transfer reflect standards used by networks such as the European Genome-phenome Archive and data-sharing agreements seen in consortia like the International Rare Diseases Research Consortium.
Registry analyses have influenced clinical pathways at specialist centers including Great Ormond Street Hospital and Royal Brompton Hospital, shaped newborn screening policies analogous to programmes in Sweden, France, and United Kingdom, and contributed to health-technology assessments by agencies such as National Institute for Health and Care Excellence and Haute Autorité de Santé. The Registry’s evidence has supported access to therapies marketed by companies such as Vertex Pharmaceuticals and influenced outcome measures adopted by trialists at University of Cambridge and Utrecht University Hospital. Its role in benchmarking has assisted national health services like NHS England and policy forums within the European Commission to prioritize care for people with cystic fibrosis.
Category:Medical registries